STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCSA
  4. [Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity

Processa (PCSA) CFO reports RSUs and options grant on Oct 1, 2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Processa Pharmaceuticals (PCSA) reported a Form 4 for its Chief Financial Officer, reflecting equity grants dated October 1, 2025. The filing shows an award of 108,000 Restricted Stock Units (RSUs) and stock options for 324,000 shares at an exercise price of $0.198 per share.

The RSUs vest one-third on October 1, 2026, then one-thirty-sixth each month until fully vested on October 1, 2028. The options vest one-third on the first anniversary of the grant date, with the remainder vesting ratably over the following two years. After these transactions, the filing lists 108,000 RSUs and 324,000 options beneficially owned, held directly.

Positive

  • None.

Negative

  • None.
Insider SKIBSTED RUSSELL
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Restricted Stock Units 108,000 $0.00 --
Grant/Award Stock Options (Right to Buy) 324,000 $0.00 --
Holdings After Transaction: Restricted Stock Units — 108,000 shares (Direct); Stock Options (Right to Buy) — 324,000 shares (Direct)
Footnotes (1)
  1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SKIBSTED RUSSELL
(Last) (First) (Middle)
C/O PROCESSA PHARMACEUTICALS, INC.
601 21ST STREET SUITE 300
(Street)
VERO BEACH FL 32960
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 10/01/2025 A 108,000 (1) (1) Common Stock 108,000 $0 108,000 D
Stock Options (Right to Buy) $0.198 10/01/2025 A 324,000 (2) (2) Common Stock 324,000 $0 324,000 D
Explanation of Responses:
1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.
2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did PCSA's CFO report on Form 4?

The CFO reported 108,000 RSUs and 324,000 stock options at an exercise price of $0.198 per share as of October 1, 2025.

What is the vesting schedule for the PCSA CFO's RSUs?

RSUs vest one-third on October 1, 2026, then one-thirty-sixth monthly until fully vested on October 1, 2028.

How do the PCSA CFO's options vest and at what price?

Options have a $0.198 exercise price, vest one-third on the first anniversary of the grant, then ratably over the next two years.

How many derivative securities are listed as beneficially owned after the transactions?

The filing lists 108,000 RSUs and 324,000 stock options beneficially owned following the reported transactions.

What is the ownership form reported for these PCSA awards?

Both the RSUs and stock options are reported as held directly.

Who is the reporting person and role at PCSA?

The reporting person is the company’s Chief Financial Officer of Processa Pharmaceuticals, Inc. (PCSA).